| Astrocytes are critical for maintaining the homeostasis of the CNS. Increasing evidence suggests that a number of neurological and neuropsychiatric disorders, including chronic pain, may result from astrocyte 'gliopathy'. Indeed, in recent years there has been substantial progress in our understanding of how astrocytes can regulate nociceptive synaptic transmission via neuronal-glial and glial-glial cell interactions, as well as the involvement of spinal and supraspinal astrocytes in the modulation of pain signalling and the maintenance of neuropathic pain. A role of astrocytes in the pathogenesis of chronic itch is also emerging. These developments suggest that targeting the specific pathways that are responsible for astrogliopathy may represent a novel approach to develop therapies for chronic pain and chronic itch.
Astrocytes account for approximately 20-40% of all the glial cells in the CNS 1 . Historically, they were thought principally to provide structural and nutritional support for neurons; however, it is now appreciated that they also play an active role in many critical neural processes 2 . Unlike other non-neuronal CNS cell types, such as microglia and oligodendrocytes, astrocytes are physically coupled to one another by gap-junction protein complexes, which directly link the cytosol of adjoining cells in order to allow free exchange of ions and small cytosolic components 3 . Astrocytes can also be distinguished from other CNS glial cell types by their expression of glial fibrillary acidic protein (GFAP), which is present in all of their major branches and processes and dynamically changes during their transition to reactive states after insult or injury 4, 5 Importantly, each astrocyte occupies a non-overlapping territory or domain with the CNS [6] [7] [8] . Although the functional significance of this territorial organization is not fully understood, it appears to be disrupted during the transition of astrocytes to reactive states 8 . Additionally, a key discerning feature of astrocytes is their extensive contact with cerebral blood vessels, which allows them to modulate blood flow during neuronal activation 7 .
Astrocytes also have extensive contacts with interneuronal synapses; a single cortical astrocyte in the rodent brain can enwrap as many as 140,000 synapses and contact 4-6 neuronal soma and 300-600 neuronal dendrites [9] [10] [11] [12] . It is important to note that the astrocytes of different species vary considerably in their sizes and morphological complexity 11, 13 . Furthermore, the human brain contains several subtypes of astrocytes that are not present in rodents 11, 13 . The diameter of human cortical astrocytes is twice as large as that of their rodent counterparts, and they can extend 10 times as many primary processes. Furthermore, a single human astrocyte may make contact with up to 2 million synapses 6, 11 .
Interestingly, there is evidence to suggest that the increased morphological complexity of astrocytes that has occurred with primate phylogeny may subserve increased cognitive function 14 .
Mounting evidence suggests that astrocytes are key regulators of CNS diseases -including neurodegenerative, neuropsychiatric and neurodevelopmental diseases and gliomas [15] [16] [17] -in which they drive pathogenesis in part through the regulation of neuroinflammation [18] [19] [20] [21] [22] .
Chronic pain, now recognized as a distinct disease that can be caused by many different aetiologies, emerges as a result of activity-dependent synaptic changes that lead to the sensitization of the pain circuitry 23 . This sensitization is characterized by an increase in excitatory synaptic transmission and a loss of inhibitory synaptic transmission in pain circuits in the CNS (central sensitization) 23, 24 . Importantly, there is increasing agreement that astrocytemediated neuroinflammation is a key mechanism underlying the maintenance of chronic pain 24, 25 .
This Review focuses on the major advances that have been made in our understanding of the role of astrocytes in the pathogenesis of neuropathic pain (Box 1), a chronic pain condition in which the role of glia has been wellinvestigated. We will highlight the emerging literature supporting a role for astrocytes in the modulation of pain under homeostatic conditions (that is, in the absence of pathology) and discuss new evidence supporting the notion that astrocyte-mediated neuroinflammation is a central driver of neuropathic pain. We will highlight important differences in the distinct roles of microglia and astrocytes in the induction and maintenance of chronic neuropathic pain and describe how crosstalk between astrocytes, neurons and microglia promotes pain pathogenesis in mammalian systems. We will also discuss the intersection of the pain and itch pathways and describe the emerging role of astrocytes in the pathogenesis of chronic itch conditions. Finally, we will consider Neuroinflammation A localized form of inflammation occurring in the peripheral nervous system and/or CNS.
Central sensitization
Forms of neuronal and/or synaptic plasticity characterized by increased responsiveness of nociceptive neurons in the CNS to their normal input.
how we can target astrogliopathy as a novel strategy to treat chronic pain and its related comorbidities.
Astrocytes in homeostatic conditions
In the absence of pathology, astrocytes provide metabolic support to neurons and contribute to the maintenance of physiological levels of extracellular potassium ions (K + ), glutamate and water [26] [27] [28] (Fig. 1 ). Astrocytes connect with one another to form intercellular gap-junction communication routes via hemichannels that directly link adjacent cells. This allows astrocytes to propagate calcium waves and to contribute to the spread of multiple longdistance signalling molecules 29 . Astrocytes also form a structural barrier around synapses, thereby 'insulating' them from glutamate spillover, while providing metabolic support 30 . In addition, their close contact with synapses enables astrocytes to regulate the local interstitial ionic and chemical environment during synaptic development and transmission 31, 32 . Indeed, astrocytes play an important role in control of the formation, maturation, elimination and maintenance of synapses and support synaptic function through a variety of diffusible and contact-mediated signals 16, 33 .
The growing understanding that astrocytes play an active role in regulating synaptic transmission in the CNS has led to the proposal that astrocytic processes are active components of synapses, exchanging signals with presynaptic and postsynaptic terminals to modulate or shape synaptic transmission 34 . Evidence for glutamatedependent intracellular Ca 2+ signalling in astrocytes, leading to the release of gliotransmitters that signal to nearby neurons (gliotransmission), was the foundation of the 'tripartite synapse' theory 34 ; however, later work showed that the tripartite synapse, as classically conceived, may only exist transiently in the developing brain 35 . In mice, astrocytes downregulate Gq-coupled metabotropic glutamate receptors during development, and in adult brains they fail to release Ca 2+ from intracellular stores when exposed to glutamate 35 . Instead, brain-wide coordinated increases in the levels of Ca 2+ in astrocytes in response to startle evoked by sound or air puffs have been documented, suggesting that astrocytes contribute to a general brain response rather than to synaptic activity in a specific circuit 36, 37 . Similar global Ca 2+ increases evoked by locomotion are inhibited by α 1 adrenergic receptor antagonists, suggesting that they are correlated with whole-brain arousal 38 . Notably, astrocytes can, in a Ca 2+ -dependent manner, modulate neural network activity through the active uptake of extracellular K + (reFS 32, 39 ), an important determinant of the resting membrane potential and excitability of neurons.
Under homeostatic conditions, astrocytes also form the structural basis for the glymphatic system ( Fig. 1 ), a brain-wide fluid transport system that functions in the clearance of proteinaceous waste products, such as excess β-amyloid, tau protein and α-synuclein, as well as their metabolic by-products 40, 41 .
Astrocytes in pain modulation
There is emerging evidence that astrocytes in the spinal cord dorsal horn (SDH) inhibit pain signalling under native physiological conditions in naive animals. Astrocyte-derived ATP is hydrolysed in the extracellular space to produce adenosine, which suppresses nociception via the activation of adenosine A1 receptors expressed by sensory neurons 42, 43 . Interestingly, in a transgenic mouse model in which gliotransmission is attenuated through the glial-specific overexpression of a dominant-negative SNARE domain (dnSNARE mice), there was a reduction in mechanical pain thresholds, suggesting that gliotransmission may modulate baseline mechanical nociception and inhibit pain under normal physiological conditons 44 . Later studies, however, have questioned the specificity of dnSNARE expression in astrocytes 45 . Spinal astrocytes also produce type-I interferons (IFN-Ι), anti-inflammatory cytokines that inhibit spinal cord nociceptive synaptic transmission and pain by binding to IFN-I receptors on the primary afferent presynaptic terminals in the SDH 46 . Downregulation of connexin 43 (CX43), the predominant gap-junction protein that mediates intercellular communication between spinal astrocytes, in mouse astrocytes and satellite glial cells also resulted in allodynia in naive animals, through the upregulation of IL-6 (reFS 47, 48 ). Collectively, these studies support the notion that astrocytes may serve to modulate pain responses in non-pathological homeostatic conditions ( Fig. 1 ).
Spinal astrocytes in pathogenic pain
Several lines of evidence support a role of astrocytes in the pathogenesis of pain, especially neuropathic pain resulting from nerve injuries. First, a correlation has been reported between astrocyte hypertrophy in the SDH and pain hypersensitivity after peripheral nerve injury in mice and rats 49 . In addition, SDH astrogliosis -a reactive response of astrocytes that is characterized
Box 1 | Chronic pain and neuropathic pain
Whereas chronic pain is a general term that constitutes any persistent pain state, regardless of the underlying aetiology, neuropathic pain was recently redefined by the International Association for the Study of Pain (IASP) to comprise pain resulting from lesions or disease of the somatosensory system, which may involve damage to the peripheral nerves as well as to the spinal cord and brain 217 . Clinical neuropathic pain is complex and chronic in nature, affecting 7-10% of the human population 218 , and is associated with diabetic neuropathy, chemotherapy, major surgeries (such as amputation or thoracotomy), spinal cord injury, multiple sclerosis and stroke 219 . Neuropathic pain symptoms include hyperalgesia (increased painful response to noxious stimulation), allodynia (painful response to normally innocuous stimulation, such as light touch) and spontaneous pain (such as 'burning' pain). Of these, mechanical allodynia (tactile allodynia) and cold allodynia are cardinal features of neuropathic pain. Neuropathic pain has accompanying affective aspects and is also associated with depression, anxiety and insomnia.
Commonly used animal models for neuropathic pain include the chronic constriction injury model, the spinal nerve ligation model, the partial sciatic nerve injury model and the spared nerve injury model [220] [221] [222] [223] . Increasing numbers of studies are using models of neuropathic pain with particular clinical relevance, such as chemotherapy-induced peripheral neuropathy models that use chemotherapy agents such as paclitaxel, oxaliplatin, bortezomib and vincristine 82, 224 . Spinal cord injury is also frequently used to study central neuropathic pain, glial activation and neuroinflammation 63, 112 .
mechanistically, neuropathic pain is a maladaptive response of the nervous system to damage and is driven by neural plasticity, including peripheral sensitization in primary sensory neurons and central sensitization in the spinal cord and brain 23 . mounting evidence suggests that neuroinflammation, resulting from the activation of microglia and astrocytes, plays a critical role in the development and maintenance of neuropathic pain 18,77,81,85,219,225-227 . by morphological, molecular and functional changes (Box 2) -has consistently been observed following a variety of injuries leading to chronic pain (reviewed in reF. 9 ). For example, robust astrogliosis (indicated by increased GFAP expression) is induced in rodents by nerve trauma and spinal cord injury [49] [50] [51] [52] , chronic opioid exposure 53 , intraplantar or intra-articular injection of complete Freund adjuvant (CFA) [54] [55] [56] [57] , bone 58 and skin cancer 59 , chemotherapy, and HIV-induced neuropathy 60 . Although insight into the reaction of human astrocytes to each of these pathologic states has been limited by the availability of tissue, analysis of post-mortem spinal cord tissue has demonstrated astrocyte activation in the SDH of HIV-positive patients 61 and patients with longstanding complex regional pain syndrome 62 , indicating that astrogliosis also occurs in association with chronic pain in humans.
In mouse models of neuropathic pain, the time course of astrogliosis -which is induced early and is sustained for exceptionally long durations -points to a role for this reaction in both the acute-to-chronic pain transition and the maintenance phase of pain. For example, in rats, GFAP upregulation remains prominent nine months after spinal cord injury, at which time the reactions of other cell types, such as microglia, have subsided 63 . In further support of this idea, it has been shown that interfering with astrogliosis can modulate neuropathic pain. For example, inhibiting the increased proliferation of spinal astrocytes that is observed in the rodent SDH after nerve injury reduces neuropathic pain 64 . Other studies have shown that the inhibition of GFAP expression and astrogliosis after nerve injury is correlated with a reduction in neuropathic pain behaviours (reviewed in reF. 4 ). That is, mice lacking Gfap exhibited neuropathic pain states with similar onset but a shortened duration after nerve injury compared to wild-type mice 65 . Intrathecal (spinal) knockdown of GFAP expression with antisense oligonucleotide treatment in nerve-injured animals also reduced neuropathic pain behaviours 65 . However, GFAP is also expressed by peripheral glial cells that are involved in pain regulation (such as satellite glial cells in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve), making the cellular basis of this analgesic effect ambiguous 4 . Finally, spinal inhibition of signal transducer and activator of transcription 3 (STAT3)-mediated signalling, which drives the proliferation of astrocytes in the spinal cord after nerve injury, reduces the number of proliferating astrocytes, with a corresponding recovery from neuropathic pain 64 .
In a second line of evidence linking astrocytes with pain, gain-of-function studies have shown that spinal astrocyte-derived mediators are sufficient to produce pain hypersensitivity. For example, it was shown that transgenic expression of the pro-inflammatory cytokine tumour necrosis factor (TNF) by astrocytes increases mechanical allodynia in a mouse neuropathy model 66 . Furthermore, mice overexpressing C-C motif chemokine 2 (CCL2) in astrocytes display enhanced hyperalgesia 67 . Consistent with these findings, an intrathecal injection of TNF-treated astrocytes evokes persistent mechanical allodynia in mice through a mechanism involving the release of CCL2, demonstrating that the adoptive transfer of activated astrocytes is sufficient to induce pain symptoms 68 .
A third, and crucial, line of evidence linking astrocytes with pain is provided by the direct manipulation of astrocyte activity using pharmacological and optogenetic approaches. Early studies that utilized astrocyte toxins, metabolic inhibitors that are preferentially taken up by astrocytes, or the astrocyte-enriched enzyme glutamine synthetase in rats suggested a probable role for astrocytes in pain 4, 69 . Although none of these toxins is specific for astrocytes, their selectivity is improved when they are administered via a local intrathecal route that mainly targets spinal cord cells. To date, a large number of studies utilizing these compounds in a variety of acute and chronic pain models have observed attenuated pain behaviours, directly linking astrocytes with the induction and maintenance of inflammatory and neuropathic pain 9, 56, [69] [70] [71] [72] [73] [74] [75] . A recent study demonstrated that transient optogenetic stimulation of spinal astrocytes could produce mechanical allodynia in naive rats as rapidly as 1 hour post-stimulation, indicating that astrocyte activation is sufficient to drive the induction of pain 76 . Future studies that use emergent technologies, such as inhibitory chemogenetics, to specifically target astrocytes or astrocyte activation are warranted, to further strengthen this link. Nevertheless, we believe that the breadth of the current published literature clearly points to astrocytes as crucial drivers of pathological pain.
Astrocytes versus microglia in pain
Although this Review focuses on the role of astrocytes in chronic neuropathic pain, spinal microglia activation is also a key feature of several types of neuropathic pain (Box 1). The contribution of microglia to the pathogenesis of chronic neuropathic pain is well-established and has been comprehensively discussed in several elegant reviews 4, 22, 75, [77] [78] [79] [80] [81] . However, important differences exist between spinal microgliosis and astrogliosis in the context of pain. Whereas astrocytes contribute to nearly all persistent pain conditions, microglia appear to regulate only certain types of pain conditions 4 . For example, whereas nerve injury results in the activation of both microglia and astrocytes, chemotherapy-induced peripheral neuropathy (CIPN) in rats is associated with marked astrogliosis, but little or no microgliosis 82 . Furthermore, in the SDH of HIV-infected patients, chronic pain is associated with markers of astrogliosis but not of microgliosis 61 . In some conditions, such as in rodent bone cancer models of neuropathic pain, there are conflicting reports on whether microglia are activated, but the occurrence of reactive astrogliosis is not disputed 4 . Underscoring the selective contributions of microglia and astrocytes to different types of chronic pain, the inhibition of microglial intracellular signalling pathways, such as the p38 mitogen-activated protein kinase (MAPK) pathway, reduces neuropathic pain symptoms in mice after nerve trauma but not in CIPN 83, 84 . There are also important sex differences in the involvement of astrocytes versus microglia in chronic pain; whereas inhibitors that preferentially target astrocytes reduce neuropathic pain in both male and female mice, microglial inhibitors are only able to attenuate neuropathic pain in male mice Hyperalgesia increased pain in response to a stimulus that ordinarily provokes pain.
Optogenetic
The use of light to activate or inhibit genetically encoded ion channels expressed within a defined cell type of interest. NaTuRe RevieWs | NeuRoSCieNCe in inflammatory pain and neuropathic pain models [84] [85] [86] (although the male-specific functions of microglia in pain pathogenesis may not apply to all the pain conditions 87 ). Furthermore, a recent study has shown that loss of the voltage-gated sodium channel subtype Nav1.5 from astrocytes leads to worsened neuroinflammation and to clinically related symptoms in experimental autoimmune encephalomyelitis (EAE), a mouse model that is known to produce pain in female but not male mice 88 . Both the time course and duration of gliosis following nerve injury also differ between microglia and astrocytes. Although the precise time course of disease varies depending on the individual study and injury model, microglial activation generally precedes and subsides prior to astrocyte activation. For example, following peripheral nerve injury in mice, spinal microglia rapidly proliferate and undergo morphological changes, reaching maximal levels within the first week following injury 81 . This reaction is transient and self-limiting, returning to baseline levels within 3 weeks. By contrast, astrogliosis is evident one week after nerve injury and persists for many months 4, 89 . Studies using inhibitors that preferentially target astrocytes have demonstrated efficacy in attenuating both early and late phases of neuropathic pain, whereas microglial inhibitors are effective primarily in the early phase 90, 91 , thus correlating well with the kinetics of activation. For these reasons, microglia and astrocytes are posited to play distinct roles in the induction, maintenance and resolution of chronic pain, with microgliosis contributing to its onset and reactive astrocytes contributing to its later stages. This generalized model of neuropathic pain pathogenesis has been shown to be grossly accurate, although important differences emerge, depending on the specific model investigated and the precise experimental definition of 'gliosis' . Notably, in a bone cancer pain model in female rats, astrogliosis precedes microgliosis in the spinal cord and delayed microglia activation plays an active role in maintaining cancer pain 87 . Furthermore, optogenetic activation of astrocytes is sufficient to elicit microglial activation 76 , suggesting that there are bilateral interactions between microglia and astrocytes in pain states.
Last, but not least, astrocytes and microglia may differ in their contributions to nociception more generally. Whereas astrocytes can modulate baseline pain sensitivity under physiological conditions (as described above), a corresponding role of microglia has not yet been demonstrated.
Astrocyte signalling in chronic pain
Many cell types interact with nociceptive neurons and contribute to the pathogenesis of neuropathic pain through distinct signalling mechanisms, including Schwann cells, macrophages, keratinocytes, satellite glial cells, T cells, oligodendrocytes and microglia 21 . Here we focus on the contribution of astrocytes, and in particular, insights from recent studies into astrocytic intracellular signalling mechanisms and the actions of astrocytereleased neuromodulators after nerve injury (TABle 1) , revealing important roles for both neuron-astrocyte and microglia-astrocyte interactions in pain pathology.
Kinase and protease pathways. The MAPKs, including extracellular signal-regulated kinase 1 (ERK1) and ERK2, p38 MAPK (p38), c-Jun N-terminal kinase (JNK) and ERK5, show distinct activation patterns in SDH glial cells following nerve injury, and play different roles in neuropathic pain induction and maintenance 92, 93 . In rats, nerve injury results in increased phosphorylation of p38 (P-p38) in microglia, whereas increased phosphorylation of JNK (pJNK) is observed in astrocytes 52, 94, 95 . Consistent with these findings, transforming growth factor-activated kinase-1 (TAK1), the upstream activator of JNK and c-Jun, and the downstream effectors of JNK are also activated by nerve injury in rat spinal astrocytes (but not microglia) 52, 96 . Of the three JNK isoforms (JNK1, JNK2 and JNK3), spinal astrocytes mainly express JNK1 (reF. 55 ). Notably, intrathecal administration of the NMDA antagonist ketamine attenuated neuropathic pain by suppressing pJNK in rat astrocytes 97 . Nerve injury also results in a dynamic activation of ERK in rat SDH glial cells: microglial phosphorylated ERK (pERK) is induced in the early phase (the first week after nerve injury) but gradually reduces thereafter, whereas pERK is expressed in astrocytes during the late phase following nerve injury 98 , suggesting that pERK contributes to both the induction and maintenance of neuropathic pain.
Several proteases are also upregulated in spinal astrocytes after nerve injury. Matrix metalloproteinases (MMPs) play an active role in neuroinflammation after brain injury in rodent models 99 . Interestingly, MMP9 and MMP2 differentially regulate microglial and astroglial activation and contribute to the induction and maintenance of neuropathic pain, respectively 100 . In rodents, spinal nerve ligation (SNL) induces a rapid and transient upregulation of MMP9 in DRG sensory neurons, leading to early activation of microglia, and this is followed by late but sustained MMP2 upregulation in spinal cord astrocytes, which regulates the late phase of neuropathic pain through the activation of IL-1β 100 . Nerve injury further induces tissue type plasminogen activator (tPA) expression in rat spinal astrocytes to facilitate neuropathic pain 101 . Tetramethylpyrazine (also known as ligustrazine) is a natural compound Summary of the various supportive and neuroprotective roles of astrocytes under physiological conditions. Astrocytes wrap around synapses to provide structural support and insulation for synapses and to further regulate synaptogenesis via the expression of adhesion molecules such as hevin 234 . Astrocytes express glutamate transporters, potassium channels and water channels, allowing them to contribute to the maintenance of glutamate homeostasis, potassium homeostasis and water homeostasis, respectively 27 . Astrocytes mediate long-range (intercellular) signalling via connexin 43-mediated gap-junction communication 29 . Astrocytes in the spinal cord dorsal horn, the brainstem trigeminal nucleus and the sensory cortex (as well as in other regions) may also suppress physiological pain through the release of inhibitory molecules such as type-I interferons (IFN-Ι), which acts via its neuronal receptor, the interferon α/β receptor (IFNAR) 46 . The glymphatic system utilizes the perivascular spaces formed by the vascular endfeet of astrocytes, which plaster around the vasculature. Cerebrospinal fluid (CSF) is driven through the periarterial space by arterial pulsations 41 . The vascular endfeet of astrocytes are particularly enriched with aquaporin-4 (AQP4) channels, allowing water flow that facilitates the dispersal of CSF into the brain tissue alongside interstitial fluid (ISF). The mixture of CSF and ISF flows through the extracellular space (blue arrows indicate fluid flow) to perivenous spaces and cranial nerve tracts, permitting fluid and waste to collect in lymphatic and cervical lymphatic vessels 41, 211 . GLT1, glutamate transporter 1; GL AST, glutamate aspartate transporter ; Kir4.1, inwardly rectifying K + channel 4.1; NL-1b, neuroligin-1β; NRX-1a, neurexin-1α. ◀ NaTuRe RevieWs | NeuRoSCieNCe R e v i e w s volume 20 | NovemBeR 2019 | 671 found in fermented soya and cocoa beans that exhibits potent anti-inflammatory activities in rats and has been shown to inhibit neuropathic pain by blocking astrocytic upregulation of MMP2 and pJNK 102 .
Transporters and gap-junction proteins. The glutamate transporters GLT1 (also known as SLC1A2) and GLAST (also known as SLC1A3), which are highly (but not exclusively) expressed in astrocytes, modulate
Box 2 | Astrocyte heterogeneity and distinct functional states of astrocytes
The emergence of high-throughput and affordable single-cell sequencing technology has led to a deeper understanding of cellular diversity throughout the nervous system. Although work in this area is ongoing and rapidly evolving, at least seven distinct, regionally restricted subtypes of astrocytes have been identified in the brains of adult mice through single-cell sequencing 205, 206 (see the figure, part a, top panel). Distinct subtypes of brainstem and spinal cord astrocytes, with unique structural, molecular and functional properties have also been identified (see the figure, part a, bottom panel) 228, 229 , indicating that this cellular diversity is a common feature throughout the CNS. Functional studies investigating these distinct populations are warranted; however, the molecular and cellular diversity among astrocytes may be important in conferring regionspecific homeostatic functions. In the context of sensory neurobiology, understanding the regional diversity in critical regions such as the somatosensory cortex and the thalamus, brainstem and spinal dorsal horn are of key importance.
In addition to regional heterogeneity, recent studies have begun to characterize phenotypic diversity among astrocytes in response to perturbations in homeostasis (see the figure, part b) . For many decades, the phrase 'astrocyte activation' was used as the prevailing terminology to describe astrogliosis, which has been historically defined using relatively nonspecific methods, including upregulation of glial fibrillary acidic protein (GFAP) and changes in astrocyte morphology. It is becoming increasingly appreciated that several distinct states of activation exist, including a pro-inflammatory 'A1' state and a proregenerative 'A2' state 207 . It is likely, however, that, under pathological conditions, astrocytes can exist in more than a simple binary state of activation, similar to recent evidence supporting a complex array of microglia phenotypes in disease states 230 . The specific phenotype of reactive astrocytes in chronic pain conditions remains to be determined; however, on the basis of the milieu of inflammatory cues produced by reactive astrocytes during the initiation and maintenance of chronic pain, it is likely that astrocytes undergo a transition to an A1-like state. It is possible that additional populations of astrocytes may also emerge with anti-inflammatory phenotypes, as has been demonstrated for microglia 81 .
It has begun to be appreciated in the inflammation field that 'anti-inflammation' and 'pro-resolution' are not identical, with the latter state involving the phagocytosis of macrophages and the production of and response to specialized proresolving mediators (SPMs), such as resolvins and protectins 231 . Notably, SPMs have potent analgesic actions in animal models of inflammatory pain and neuropathic pain, acting to regulate the functions of immune cells, glial cells and neurons through specific G protein-coupled receptors 81 . SPMs promote the resolution of inflammatory pain and neuropathic pain in part by inhibiting cytokine and chemokine release from astrocytes 232, 233 . It will be of interest to examine whether astrocytes express SPM receptors and have a pro-resolving phenotype as 'A3 astrocytes'. To fully understand the contribution of astrocytes in CNS disease pathogenesis, including chronic pain, future studies utilizing emerging technologies such as single-cell transcriptomics, translatomics and mass cytometry will be required in order to determine the specific phenotype of astrocytes (for example, their activation state) in chronic pain conditions, as well as in other disease states.
AGT + , angiotensinogen expressing; ISLR + , immunoglobulin superfamily containing leucine-rich repeat expressing; GDF10 + , growth and differentiation factor 10 expressing; MGFE8 + , milk fat globule epidermal growth factor 8 expressing; MYOC + , myocilin expressing.
Dorsal midbrain astrocytes (MYOC + )
Bergmann glia of the cerebellum (GDF10 + ) Olfactory-specific astrocytes (ISLR + ) extracellular glutamate levels in order to maintain homeostasis of the CNS in normal physiological conditions ( Fig. 1 ). Interestingly, nerve injury in rats elicits initial upregulation of GLT1 and GLAST in the rat spinal cord, followed by sustained downregulation of these proteins 103, 104 . In rats, spinal administration of Riluzole, a positive glutamate transporter activity regulator, effectively attenuated neuropathic pain 103 , whereas the inhibition of glutamate transporters increased spinal extracellular glutamate levels, leading to the development of spontaneous pain 105, 106 . More recently, a vector that selectively increases GLT1 expression in astrocytes when it is microinjected into the superficial SDH was developed and used to show that GLT1 overexpression in astrocytes reverses established neuropathic pain following spinal cord injury 107 . bFGF, basic fibroblast growth factor ; CCI, chronic construction injury ; CCL2, C-C motif chemokine 2; CCR2, C-C motif chemokine receptor 2; CX43, connexin 43; CXCL1, C-X-C chemokine ligand 1; CXCR2, C-X-C chemokine receptor 2; ERK , extracellular signal-regulated kinase; GLT1, glutamate transporter 1; GL AST, glutamate aspartate transporter ; JAK2, Janus kinase 2; JNK , c-Jun N-terminal kinase; MAP kinase, mitogen-activated protein kinase; MMP2, matrix metalloproteinase 2; NFκB, nuclear factor κB; pERK1/2, phosphorylation of ERK 1/2; pJNK1, phosphorylation of JNK 1; SDH, spinal dorsal horn; SNL , spinal nerve ligation; SNLT, spinal nerve ligation and transection; STAT3, signal transducer and activator of transcription 3; TAK1, transforming growth factor-activated kinase-1; TNF, tumour necrosis factor ; tPA , tissue plasminogen activator ; TRAF6, TNF receptor-associated factor 6; TSP-4, thrombospondin-4; WNT3A , WNT family member 3A.
NaTuRe RevieWs | NeuRoSCieNCe Expression of the water channel aquaporin-4 (AQP4) is induced in spinal cord astrocytes after spinal cord injury in rats 51 and nerve injury in humans 108 . The specific role of AQP4 in animal models of neuropathic pain remains to be determined. However, it has been hypothesized that AQP4 could be required for the maintenance of the homeostasis of the circuits mediating nociception, as mice lacking Aqp4 display reduced pain sensitivity (hypoalgesia) and dorsal horn sensitivity to noxious stimulation 109 .
Notably, AQP4 autoantibodies are present in patients with neuromyelitis optica (NMO), a painful autoimmune disease involving spinal cord and nerve injury 110 .
One of the key properties of astrocytes is their formation of intercellular gap-junction networks. CX43 is the predominant gap-junction constituent expressed in astrocytes. CX43 hemichannels can release cytosolic compounds such as ATP or glutamate when open 111 . In rodents, CX43 expression is upregulated in astrocytes following nerve lesion and spinal cord injury, and inhibition of gap-junction function by the non-selective inhibitor carbenoxolone (CBX) is effective in reversing mechanical allodynia in both mice and rats 91, 112, 113 . Evidence also suggests that nerve injury may cause a functional switch from CX43-mediated gap junctions to unopposed CX43 hemichannels, causing the extracellular release of key astrocytic mediators such as ATP, glutamate and chemokines 91, 114 . Indeed, spinal cord injury-evoked ATP release and astrogliosis in the spinal cord are both diminished in Cx43 -/and Cx30 -/knockout mice, with a corresponding reduction in neuroinflammation 115, 116 . Specific knockdown of CX43 expression via RNA interference 47,91 also attenuated mechanical allodynia after nerve injury in both mice and rats. Selective CX43 blockade was also successfully achieved using the CX43 mimetic peptides Gap26 and Gap27, resulting in late-phase neuropathic pain relief in mice 91 . Thus, persistent upregulation of CX43 is essential for maintaining neuropathic pain. Of note, CX43-mediated ATP release also serves as a mediator of intercellular astrocyte-microglial cell interactions: several ATP receptors, including P2X purinoreceptor 4 (P2RX4), P2RX7 and P2Y purinoreceptor 12 (P2RY12), are upregulated in spinal microglia and are critically involved in the pathogenesis of neuropathic pain 78 (Fig. 2) .
The CX43 gap-junction blocker CBX also inhibits another gap-junction mediator, pannexin 1 (PNX1), which is expressed in both astrocytes and microglia and itself modulates ATP release 117 . In mouse spinal cord astrocytes, glucocorticoids regulate a diurnal exacerbation of mechanical allodynia after nerve injury during the late light phase through glucocorticoid-inducible kinase-1 (SGK-1) and PNX1-mediated ATP release 118 . In addition, microglial PNX1-mediated release of IL-1β has been implicated in the mechanisms of mechanical allodynia in an osteoarthritis model of joint pain 119 , demonstrating roles for both astrocyte-derived and microglia-derived ATP in promoting neuropathic pain.
Glial mediators and neuromodulators. Peripheral nerve injury induces the expression of chemokines such as CCL2 and C-X-C chemokine ligand 1 (CXCL1) in mouse spinal cord astrocytes 91, 120 . In primary cultures of astrocytes, TNF rapidly induced expression of the pro-nociceptive chemokines CCL2, CXCL10 and CXCL1 through the upregulation of JNK, demonstrating cytokine-chemokine crosstalk in the pathogenesis of chronic pain 120 . Indeed, as we discussed above, intrathecal injection of TNF-activated mouse astrocytes results in persistent mechanical allodynia via the release of CCL2 and CXCL1 in the SDH, whereas intrathecal neutralization of CCL2 and CXCL1 with neutralizing antibodies attenuates mechanical allodynia in murine models of neuropathic pain 91, 120 . It has also been shown that there is an increase in astrocytic CCL2 expression in the medullary dorsal horn of the brainstem following trigeminal nerve injury in mice and that this contributes to trigeminal neuropathic pain 121 . Interestingly, CX43 also regulates chemokine release. Thus, CX43 blockade in astrocyte cultures and spinal cord slices inhibits the basal release of CCL2 and CXCL1 and, furthermore, prevents the TNF-evoked release of these chemokines 91 (Fig. 2 ). CX43-mediated chemokine release may also involve other ATP-gated channels, such as PNX1 and P2RX7 (reF. 116 ). In addition to producing the chemokines CCL2 and CXCL1, mouse astrocytes also upregulate the chemokine receptor CXCR5 following SNL 122 . This study also demonstrated a marked reduction in the development of neuropathic pain symptoms such as mechanical allodynia and heat hyperalgesia in Cxcr5 knockout mice, as well as reduced reactive astrogliosis after SNL. Furthermore, it was demonstrated that spinal infusion of the CXCR5 ligand CXCL13, which is produced by SDH neurons, is sufficient to activate SDH astrocytes and to elicit allodynia and hyperalgesia in wild-type mice (but not in Cxcr5 knockout mice) 122 .
WNT proteins are a family of secreted signalling molecules that regulate various cellular processes, including neuroinflammation in disease states 18, 123 . In mice and rats, nerve injury resulted in rapid and sustained upregulation of WNT3A and WNT5B, prototypical WNT ligands, as well as the activation of signalling via the WNT-frizzled-β-catenin pathway in neurons and astrocytes in the SDH 124, 125 . Spinal inhibition of WNT signalling pathways suppressed the development and maintenance of neuropathic pain in these animals and, furthermore, blocked the nerve injury-induced astroglial reaction and neuroinflammation, supporting the notion that WNT signalling is an important mediator of neuropathic pain symptoms 124 (Fig. 2) .
Recently, evidence has also implicated sphingolipids in astrocyte signalling and in the pathogenesis of neuropathic pain. Unbiased mass spectrometry-based metabolomics revealed significant changes in the ceramide catabolite N,N-dimethylspingosine (DMS) in the rat DRG and SDH following peripheral nerve injury. Furthermore, intrathecal administration of DMS in naive rats induced persistent mechanical allodynia that was associated with reactive astrogliosis 126 . In addition, treatment of cultured astrocytes with DMS led to their release of CCL2 and IL-1β 126 . CIPN is a dose-limiting factor of various chemotherapy drugs such as paclitaxel and bortezomib. A recent study showed that bortezomib administration in rats causes mechanical allodynia that correlates with increased biosynthesis of ceramide metabolites -including the sphingosine-1-phosphate receptor 1 (S1PR1) ligands S1P This involves a change in morphology , including a reduced complexity of astrocytic processes and a thickening of the main processes, the upregulation of glial fibrillary acidic protein (GFAP) and connexin 43 (CX43), and the activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) signalling via phosphorylation (pERK , pJNK). The collective activation of these signalling pathways leads to the release of astroglial mediators, which alter neural excitability through modulation of excitatory and inhibitory synaptic transmission, leading to central sensitization and neuropathic pain and transition from acute to chronic pain 4 . The activation of astrocytes in neuropathic pain conditions results in the upregulation of CX43 expression and a functional switch in CX43-mediated function from gap-junction communication to CX43 hemichannel-mediated paracrine signalling, resulting in increased release of pro-inflammatory chemokines (C-X-C chemokine ligand 1 (CXCL1) and C-C motif chemokine 2 (CCL2)), as well as of glutamate and ATP. Spinal microglia express several receptors for ATP (including P2X purinoreceptor 4 (P2RX4), P2RX7 and P2Y purinoreceptor 12 (P2RY12)) 78, 81 , and the activation of these microglial receptors induces the release of pro-inflammatory cytokines (including tumour necrosis factor (TNF) and IL-1β), leading to the sensitization of dorsal horn neurons. These cytokines also activate the pJNK and pERK pathways in astrocytes, further increasing their production and release of pro-inflammatory chemokines. The release of astrocytic mediators (including CXCL1, CCL2 and IL-1β) promotes central sensitization via the neuronal receptors C-X-C chemokine receptor 2 (CXCR2), C-C motif chemokine receptor 2 (CCR2) and IL-1 receptor (IL-1R), which further stimulate ERK signalling in primary afferent central terminals and SDH neurons 91, 120 . Nerve injury-evoked release of CXCL13 from SDH neurons also activates astrocytes via the CXCR5 receptor, thus facilitating neuropathic pain 122 . In the inset, the activation of cytokine receptors (including tumour necrosis factor receptor (TNFR) and IL-1R) and Toll-like receptor 4 (TLR4) in astrocytes, by endogenous ligands and cytokines released from microglia and other astrocytes following nerve injury , results in upregulation of the transcriptional regulator TNF receptor-associated factor 6 (TRAF6) and subsequent activation of the pERK and pJNK pathways, leading to the release of astroglial mediators, including chemokines, to facilitate neuropathic pain 132 . Astrocytes may also release growth factors including WNT family member 3A (WNT3A) and fibroblast growth factor 2 (FGF2) in order to regulate neuropathic pain 72, 124 . GluRs, glutamate receptors. and dihydro-S1P -in the SDH. Interestingly, astrocytespecific deletion of S1pr1 under the control of the Gfap promoter blocked the onset of neuropathic pain after administration of bortezomib 127 .
Transcriptional regulators. Several transcription factors and regulators of gene expression have also been
shown to be upregulated in spinal cord astrocytes in neuropathic pain. In addition to the c-Jun pathway 52 , upregulation of members of the Janus kinase (JAK) family, leading to subsequent activation of the transcription factor STAT3 regulates astroglial proliferation and sustained neuropathic pain in rats following injury 64 . Additionally, the IL-33 receptor IL-1 receptor-like 1 (IL1RL1, also known as ST2) contributes to neuropathic pain through glial activation 128 , possibly by acting as an upstream activator of the JAK2-STAT3 pathway in the SDH 129 . Nuclear factor κB (NFκB) is another key transcription factor in induction of the expression of inflammatory genes. Nerve injury in rats and mice upregulates NFκB in spinal microglia in the induction phase (by day 3 after injury) 130 , and in spinal astrocytes during the early maintenance phase (by day 7 after injury) 131 , thus inducing and maintaining neuropathic pain symptoms. Additionally, TNF receptor-associated factor 6 (TRAF6) is critically involved in signal transduction by members of the TNF receptor and IL-1 receptor superfamily and in the regulation of gene transcription via NFkB, and TRAF6 has also been shown to play a role in the maintenance of neuropathic pain 132 . Spinal nerve injury in mice induces TRAF6 expression, primarily in astrocytes, by day 10 after injury, as well as in some microglia on day 3 after injury 132 . TRAF6 regulates CCL2 expression in astrocyte cultures through the activation of JNK 132 . Moreover, spinal knockdown of murine TRAF6 expression partially reversed SNL-induced neuropathic pain and spinal CCL2 expression 132 , demonstrating an intersection between TRAF6 and transcription of the genes encoding pro-inflammatory chemokines.
Toll-like receptors (TLRs) are key regulators of the NFkB signalling pathway and of the subsequent synthesis of cytokines and chemokines in chronic pain 133 . TLR4, the best-studied member of the TLR family, regulates neuropathic pain through its activation of microglia and astroglia in the SDH of mice and rats 134 . In addition, TLR4 is expressed by SDH astrocytes and contributes to the pathogenesis of CIPN-associated neuropathic pain in mice and rats 135 . Spinal TLR4 was shown to regulate inflammatory and neuropathic pain in male but not female mice 136 , reminiscent of the reported gender difference in the role of microglia in neuropathic pain. Gender differences in pain sensitivity and analgesia are well-documented 137 , and further studies are warranted to investigate the gender dimorphism of TLR4 in CIPN, as well as the role of other TLRs in chronic pain states between genders.
Astrocytes in central sensitization
Central sensitization is a form of synaptic plasticity in the spinal cord and brain that drives increased neuronal responsiveness in central pain pathways after priming by initial painful insults [138] [139] [140] . There is an increasing appreciation that neuroinflammation drives central sensitization during the development and maintenance of chronic pain 24 . In particular, neuroinflammation and central sensitization are responsible for widespread pain extending beyond the initial injury site (if such an injury site exists) in chronic pain conditions such as fibromyalgia and migraine 24 . Activation of NMDA receptors, phosphorylation of ERK and the loss of inhibitory input (disinhibition) in SDH neurons are key signatures of central sensitization 139, 141, 142 . Following painful insults, astrocyte-mediated neuroinflammation drives central sensitization via neuron-glial and glia-glial interactions (Fig. 2) . Notably, pro-inflammatory cytokines and chemokines, produced by astrocytes and microglia, are important for the induction and maintenance of central sensitization.
As we described above, chemokines serve as potent mediators for neuron-glial interactions in pathological pain 143 . Astrocyte-derived CCL2 and CXCL1 directly regulate central sensitization and pain via their neuronal receptors, CCR2 and CXCR1, respectively 143 . In mice, CCR2 is expressed by DRG and SDH neurons [144] [145] , and the exposure of spinal cord slices to CCL2 induces rapid pERK activation and ERK-dependent potentiation of NMDA currents in SDH neurons via the activation of CCR2 receptors 120, 145 . CCL2 also produces disinhibition in spinal cord neurons by suppressing GABAmediated transmission 146 (Fig. 2 ). In addition, CXCL1 induces ERK activation and neuronal plasticity in SDH neurons via CXCR2 receptors 147 . Nerve injury results in long-term central sensitization, as reflected by persistent increases in excitatory postsynaptic currents (EPSCs) in the mouse spinal cord pain circuit 3 weeks after injury 91 . Notably, both this late-phase spinal synaptic plasticity and central sensitization, as well as late-phase neuropathic pain, are reversed by the CXCR2 antagonist SB225002 (reF. 91 ). Conversely, neuron-derived CXCL13 drives astrocyte activation and neuropathic pain indirectly via CXCR5 expressed by SDH astrocytes 122 . Thus, a neuron-to-glial CXCL13-CXCR5 signalling axis drives both neuropathic pain and astroglial activation.
IL-1β and TNF are two major pro-inflammatory cytokines that are critically important for the pathogenesis of pain [148] [149] [150] . IL-1β expression is induced in rat SDH astrocytes and microglia after nerve injury and in bone cancer 151 . Caspase-1 cleaves and activates IL-1β and thus serves as a key component of the inflammasome during the pathogenesis of chronic pain 152 . MMP2 also plays a role in the cleavage and activation of IL-1β and astroglial activation in SDH, contributing to the maintenance of SNL-induced neuropathic pain in mice and rats 100 . IL-1β induces central sensitization in spinal pain circuits through multiple mechanisms, including presynaptic modulation of glutamate release 153 , postsynaptic regulation of NMDA receptor phosphorylation and function 56, 151, 153 and suppression of inhibitory synaptic transmission 153 . TNF is expressed by 90% of microglia and 40% of astrocytes in the SDH, but not by neurons 154 . Like IL-1β, TNF facilitates central sensitization via the regulation of both excitatory and inhibitory synaptic transmission 153, 155 .
These glia-produced cytokines and chemokines are also key regulators of spinal cord long-term potentiation
Analgesia
The absence of pain in response to stimulation that would normally be painful.
Inflammasome
A multimeric intracellular signalling complex responsible for the detection of pathogenic microorganisms and hostderived stressors, leading to the activation of caspase-1 and the induction of inflammation.
www.nature.com/nrn (sLTP) 156, 157 . sLTP is a special type of central sensitization but is not the only mechanism of central sensitization 139 . TNF signalling regulates sLTP via TNF receptor 1 (TNFR1) and TNFR2, which are present on both preand postsynaptic neuron terminals, to regulate neurotransmitter release and increase the activities of AMPA and NMDA receptors 158, 159 . IL-1β also regulates sLTP at both excitatory 160 and inhibitory synapses in SDH 161 . Furthermore, treatment with a CCR2 antagonist inhibits sLTP, even when it is administered in the maintenance phase of neuropathic pain 145 . Intriguingly, it has been demonstrated that astroglia-derived diffusible messengers such as d-serine can promote sLTP after travelling long distances through circulating cerebrospinal fluid (CSF) 162 . Likewise, the transfer of spinal CSF from a donor animal displaying sLTP can induce sLTP in a naive recipient animal 162 .
Supraspinal astrocytes in chronic pain
Although most studies have focused on glial reactions to nerve injury in the spinal cord, a host of studies have observed astrocyte activation in the spinal trigeminal nucleus in the brainstem. Similar to the role of the spinal cord in the processing of peripheral nociception, this region has a role in the processing of pain in the trigeminal system, following trigeminal nerve injury 74 or masseter inflammation 56 . Activation of astrocytes in the spinal trigeminal nucleus has been shown to contribute to persistent orofacial pain 56, 74 . Furthermore, administration of the astroglial toxin fluorocitrate can attenuate hyperalgesia following injury to the masseter or tooth pulp in rats 56, 163 and can reduce facial pain following nerve injury in rats 74, 164 . The activation of astrocytes in the spinal trigeminal nucleus appears to share many features with spinal astrocytes; for example, astrocytic upregulation of GFAP, CX43 and IL-1β expression occurs following masseter injury in rats 56 . Additionally, astrocytes in the spinal trigeminal nucleus express the purinergic receptor P2RX3, and pharmacologic inhibition of P2RX3 in rats can attenuate facial pain following chronic constriction injury of the trigeminal infraorbital nerve 165 . In human patients, postmortem studies demonstrating pain-induced astrocyte activation in the trigeminal system are lacking; however, in one study of 17 patients with orofacial neuropathic pain, functional MRI (fMRI) imaging revealed slow oscillatory activity through the ascending trigeminal pain pathway, which was absent in healthy control subjects and could not be evoked by an acute pain stimulus. This activity was proposed to be due to calcium waves propagated by activated astrocytes in patients with neuropathic pain 166 , suggesting that astrocyte activation may contribute to pain pathogenesis in both rodents and humans.
Evidence from animal models and human patients has also demonstrated that astrocyte activation occurs in higher brain regions associated with pain processing. Astrocyte activation was observed in the rostral ventromedial medulla of the brainstem following nerve injury via ligation of the infraorbital nerve, and this activation modulated trigeminal neuropathic pain via TNF and IL-1β signalling in rats 167 . Astrocyte activation in the ventrolateral periaqueductal grey, a key component of the descending pain modulation system, facilitates bone cancer pain in rats 168 . Additionally, astrocyte activation has been observed in other brain centres involved in pain processing, including parts of the anterior cingulate cortex following formalin injection, as well as the primary somatosensory (S1) cortex and thalamus following nerve injury in rats 169, 170 . A study using in vivo two-photon calcium imaging investigated the activation of astrocytes in S1 in a mouse model of mirror-image pain, in which neuropathic pain occurs on the side contralateral to the injury site 170 . The authors observed enhanced calcium transients in S1 cortical astrocytes following contralateral nerve injury, and the inhibition of astrocytes was able to attenuate synaptic remodelling and pain behaviours. Astrocytic release of thrombospondin-1 (TSP-1) is thought to be responsible for synaptic remodelling in the S1 cortex after injury 170 . In humans, imaging studies conducted on the brains of patients with chronic lower back pain have demonstrated glial activation in multiple brain regions, including the thalamus and somatosensory cortex 171 , thus indicating possible astrocyte activation in higher brain regions in humans. Future studies aimed at identifying the role of activated astrocytes in higher brain regions are warranted, and it will be of interest to determine whether there is also concomitant neuronal activation. Recently it was shown that optogenetic astrocyte activation evokes a blood-oxygen-level dependent (BOLD) fMRI response indicative of oxygen consumption, but without modulation of neuronal activity in the brain; 172 however, the relevance of this finding to pain remains to be established.
Astrocytes in chronic itch
Pain and itch are distinct sensory modalities. Whereas pain leads to withdrawal responses following noxious stimulation, itch (pruritus) leads to scratching. Pain is also known to suppress itch, underlying the observation that the intrathecal application of analgesics such as morphine leads to excessive itching in rodents, primates and humans [173] [174] [175] . Itch is elicited by various skin pathologies, and it has long been known that local dermal immune cells such as histamine-releasing mast cells contribute to the pathogenesis of itch 176 . The past decade has seen tremendous progress in elucidating the neuronal mechanisms of itch, including peripheral mechanisms such as itch receptors and itch transduction pathways, as well as the central mechanisms and neuronal pathways for the perception of itch 177, 178 . Furthermore, the spinal cord neurocircuit responsible for the suppression of itch by pain has been identified 177, 179, 180 . For example, glutamate release from nociceptors via the vesicular glutamate transporter VGLUT2 is required in order to both sense pain and suppress itch 181 . Notably, TLRs, which are widely expressed in immune cells, glial cells (microglia and astrocytes) and neurons, have been implicated in itch 182 .
Whereas acute itch is associated with short-duration pruritic stimuli, chronic itch is an intractable symptom of inflammatory skin diseases and certain types of skin cancers 183, 184 . The mechanisms implicated in chronic itch include peripheral sensitization and central sensitization of the itch circuitry 185 . One of the most striking differences between acute itch and chronic itch is the loss of inhibition -compromise of the neural circuit by which pain suppresses itch in chronic itch conditions (Fig. 3) that leads to a vicious cycle of itching and scratching 186 . In this condition, scratching paradoxically exacerbates the itch sensation. Loss of inhibitory interneurons expressing the transcription factor BHLHB5 resulted in chronic itch and severe skin lesion due to non-stop scratching in rodents, indicating that these neurons are responsible for the suppression of itch by pain 186 .
The study of itch is a newly emergent field and remains a work in progress. Given the current knowledge gaps, in both our understanding of the neurocircuitry of itch and the mechanisms underlying itch pathogenesis, the biology of itch continues to attract considerable attention. Although our understanding of the role of astrocytes in itch is still at an early stage 187, 188 , the well-established role for astrocytes in neuropathic pain, coupled with the intimate connection between the pain and itch circuitry, implies a likely role for astrocytes in itch pathogenesis. Indeed, studies have emerged that suggest a key role of spinal astrocytes in the pathogenesis of chronic itch 25, 185, 189 . First, mouse models of atopic and contact dermatitis have displayed sustained itch behaviours and long-term activation of astrocytes in SDH locations that topographically corresponded to the areas of the dermatome that were lesioned 190, 191 . Intriguingly, it has been shown that scratching plays an essential role in spinal astrogliosis during itch, because the lesion-evoked astrogliosis in the SDH can be suppressed by preventing scratching of the itchy skin 191 . In support of the idea that astrocytes play a role in the pathogenesis of itch, intrathecal administration of the astroglial inhibitor l-α-aminoadipate reduced chronic itch after dry skin injury in mice 191 . Patients with cutaneous T cell lymphoma (CTCL) suffer from severe chronic itch, and preliminary findings in a mouse model of CTCL 184 suggest that it is accompanied by persistent astrogliosis in the itch-affected SDH region (Q. Han and R.-R. Ji, unpublished observations). Although these findings suggest that astrocytes are necessary for the production of chronic itch, it is unclear whether astrocytic activation is sufficient to evoke scratching. In sharp contrast to the findings with chronic itch, astrocytes do not appear to be involved in acute itch, as l-α-aminoadipate failed to reduce scratching behaviour induced by subcutaneous administration of chloroquine or a histamine releaser 191 .
Our knowledge of the mechanisms underlying chronic pain and itch has revealed some striking similarities. TLR4, a key mediator of neuropathic pain, is induced in mouse spinal astrocytes in a chronic itch condition and is required for the development and maintenance of chronic itch 191 . Additionally, STAT3-dependent reactive astrogliosis in the SDH contributes to the pathogenesis of chronic itch: in mice, conditional disruption of astrocytic Stat3 or pharmacological inhibition of spinal STAT3 attenuated chronic itch 190 . Mechanistically, STAT3-dependent upregulation of the innate immune factor lipocalin-2 (LCN2) was shown to be crucial for inducing chronic itch. As an astrocyte-secreted mediator, LCN2 exacerbated the pruritus induced by spinal injection of gastrin-releasing peptide (GRP) 190 , which binds to its receptor GRPR in order to activate the itch circuitry in the spinal cord 178 (Fig. 3) . Additionally, a new study shows that the IL-33 receptor (ST2) is upregulated in spinal cord astrocytes in chronic itch and, furthermore, that spinal IL-33-ST2 signalling regulates chronic itch via JAK2-STAT3 cascade activation in spinal astrocytes 189 .
Itch is also related to mechanical sensations. Alloknesis, a touch-elicited itch or mechanical itch, is mediated by central sensitization 185, 192 and a spinal cord inhibitory circuit 193 . Spinal astrocytes play an activate role in alloknesis. For example, dry skin injury resulted in robust alloknesis, which was suppressed by intra thecal injection of an astroglial inhibitor or a TLR4 antagonist 191 . As in chronic pain, pro-inflammatory cytokines and chemokines in the SDH also play a role in chronic itch, and spinal inhibition of TNF reduced chronic pruritus 194 . Dry skin injury also led to an upregulation of CXCR3 and its ligand CXCL10 in the spinal cord, and intrathecal injection of a CXCR3 antagonist or deletion of Cxcr3 alleviated chronic itch 195 . These findings suggest that, in addition to the well-demonstrated peripheral actions of cytokines and chemokines in evoking pruritus in the skin [196] [197] [198] , pro-inflammatory cytokines and chemokines may drive chronic itch via astrocyte activation, neuroinflammation, disinhibition and central sensitization. These astroglia-mediated mechanisms are common to chronic pain and chronic itch conditions 185 (Fig. 3) , further demonstrating the interconnected relationship of these two distinct sensory modalities.
This observed overlap between the mechanisms driving chronic pain and chronic itch prompts an important 177, 235 . The activation of GRP + neurons in turn activates gastrin-releasing peptide receptor-expressing (GRPR + ) neurons, which connect to projection neurons that project to higher-order brain centres 178 . During homeostasis and in acute itch conditions, itch is gated by the pain circuitry , wherein the activation of primary nociceptors by scratching activates BHLHB5-expressing (BHLHB5 + ) inhibitory interneurons 186 , which inactivate both the GRP + interneurons and GRPR + projection neurons, thereby suppressing itch. Several pathological changes occur in chronic itch conditions. In the skin, chronic itch causes a hyperinnervation of the epidermis by peripheral pruriceptors, as well as increased numbers of mast cells and the presence of additional immune cell types, such as macrophages and T cells. A key feature of chronic itch conditions is the loss of pain-induced suppression of itch via the inhibition of inhibitory BHLHB5 + interneurons. As a consequence, scratching behaviours are able to go unchecked by the pain circuitry , further exacerbating the chronic itch condition. Importantly , chronic itch also induces the activation of spinal astrocytes, which release neuroinflammatory cues that drive itch pathogenesis. b | Chronic itch-induced activation of astrocytes involves activation of the transcription factor signal transducer and activator of transcription 3 (STAT3), which in turn induces the upregulation and release of lipocalin-2 (LCN2), which may activate GPR + or GRPR + neurons to promote chronic itch 190 . Chronic-itch-induced activation of astrocytes may also involve the activation of mitogen-activated protein (MAP) kinases that induce the upregulation of a milieu of proinflammatory cytokines and chemokines (including C-X-C chemokine ligand 1 (CXCL1), C-C motif chemokine 2 (CCL2) and IL-1β), which are proposed to act on presynaptic peripheral pruriceptors, postsynaptic GPR + interneurons and GRPR + neurons. The role of these pro-inflammatory cytokines/chemokines in chronic itch remains to be investigated. It is possible that the same inflammatory cytokines/chemokines regulate both chronic pain and chronic itch in distinct spinal circuits. CCR2, C-C motif chemokine receptor 2; CXCR2, C-X-C chemokine receptor 2; DRG, dorsal root ganglia; IL1R , IL-1 receptor. ◀ NaTuRe RevieWs | NeuRoSCieNCe question: if the molecular mediators are shared between these two conditions, wherein do the differences lie? It is possible that the same signalling pathways modulate both pain and itch in distinct locations and circuits. It is also possible that TLR4 and STAT3 regulate distinct downstream pathways in the pain and itch circuits. Pain and itch may coexist in some chronic conditions (such as ulcerated skin lesions), and this may be associated with a vicious cycle of 'itch-scratch-itch' , further driving astrocyte activation. Future studies aimed at dissecting these distinct sensory modalities will be needed and should focus both at the level of the neurocircuitry of these conditions and on the astroglial mediators responsible for chronic pain and itch pathogenesis.
Novel therapeutic strategies
Safe and effective treatment of chronic pain is a challenge. A recent report has stated that more than 1.5 billion people worldwide suffer from chronic pain 199 . In the USA, chronic pain conditions involving nerve injury and neurodegeneration affect 30% of the population, leading to an estimated cost of $600 billion for treatment and lost productivity 200 . Conventional pharmacological treatments, such as opiates, antidepressants and anticonvulsants, are only partially effective in managing chronic pain, frequently exacerbate pain conditions and the associated comorbidities, and are associated with significant side effects. For this reason, there is an urgent need for the development of safe, non-addictive, non-opioid-based medications that also possess disease-modifying properties.
Given the evidence supporting the notion that astrocytes play a key role in the induction and maintenance of persistent pain, it is important to consider how we can target astrogliopathy to treat chronic pain conditions. Eliminating astrocytes or blocking astrocyte function entirely by using astroglial toxins that are capable of attenuating neuropathic pain conditions in animal models is an untenable approach in human patients, given the well-established supportive and neuroprotective roles astrocytes play in organism health 6 . Additionally, developing glia-selective drugs for the treatment of neuropathic pain may prove difficult, given the very limited repertoire of astrocyte-specific targets. On the basis of our present knowledge of the astrocyte mediators of neuropathic pain, two possible strategies can be considered: targeting MAPK signalling pathways, hemichannels or purinergic receptors in order to suppress the release of glial mediators, or targeting the downstream mediators released (at least in part) by astroglia, such as chemokine and cytokine signalling. It is noteworthy that more than 80% of patients with NMO experience pain, including headache 110 . One key characteristic of NMO is the presence of serum AQP4 antibodies, and serum and CSF concentrations of IL-6, which induces AQP4 antibody production by plasmablasts, are significantly elevated in patients with NMO. Studies have shown that prolonged treatment with tocilizumab, a US Food and Drug Administration-approved anti-IL-6 antibody, may be safe and effective in treating NMO 201 as well as other neuropathic pain conditions 202 .
Given that astrogliopathy is a common feature of nearly all chronic pain pathologies, and that astroglial activation remains robust for the duration of the persistent pain condition, it is interesting to consider whether we could instead target the activation of astrocytes. In other words, can we block the transition of astrocytes to a pro-inflammatory reactive state, or favour their acquisition of a pro-resolving state, without affecting the normal homeostatic functions of astrocytes? In a sense, such a strategy would represent a movement towards an immunotherapeutic approach to treating chronic pain. Although our present knowledge of the mechanisms underlying the activation of astrocytes is lacking, in both chronic pain and other CNS diseases, the identification of astrocyte activation checkpoints represents an intriguing future therapeutic strategy.
In addition to these approaches, several nonpharmacological treatments are currently under investigation in animal models, including cell-based therapies (such as bone marrow stem cells), exercise (such as prior voluntary wheel running) and neuromodulation (including spinal cord stimulation, DRG stimulation and acupuncture), and may offer ways to control chronic pain through the regulation of astroglial reactions and neuroinflammation 24, 203, 204 .
Conclusions and future perspectives As we outlined above, chronic neuropathic pain can arise due to astrogliopathy, in which the normal capacity of astrocytes to maintain CNS homeostasis is disrupted. Astrogliopathy results in abnormal extracellular levels of glutamate, K + and water, as well as the secretion of proinflammatory cytokines and chemokines due to CX43mediated membrane leakage. These astrocyte-driven pathologies lead to neuronal hyperexcitability and neurotoxicity, neuroinflammation, and chronic pain. Importantly, astrocytes promote and maintain chronic pain conditions via neuron-glial and glia-glial interactions; astrocyte-produced mediators such as cytokines and chemokines are powerful neuromodulators regulating both excitatory and inhibitory synaptic transmission in the pain circuit, leading to central sensitization 153 . Similar dysregulations of astrocyte function may also apply to chronic itch conditions. What is the path forward? What are the knowledge gaps that remain? In our opinion, future research should focus on several key areas of importance (Fig. 4) .
It is essential to consider the functional and regional diversity of astrocytes (Box 2). Recent studies using whole-nervous system single-cell transcriptomics have revealed multiple distinct subpopulations of astrocytes based on their transcriptomes. One study, sequencing 690,000 cells taken from 9 regions throughout the mouse brain, demonstrated numerous molecularly distinct populations of astrocytes 205 . In another, sequencing over half a million cells throughout the nervous system of mice demonstrated the existence of at least seven molecularly distinct astrocyte subtypes, with region-specific distributions in the brain, and provided validation of the individual subtypes using distinct molecular markers 206 . Building upon this knowledge, understanding how distinct astroglial populations respond to chronic pain Immunotherapeutic A therapeutic agent used to treat a disease by activating or suppressing the immune system. www.nature.com/nrn and other nervous system pathologies represents an important future research direction. In addition, it is crucial that we develop a more precise definition of 'reactive astrocytes' and 'astrogliosis' , both in the context of neuropathic pain and more generally across CNS pathologies. The relatively recent demonstration of a pro-inflammatory ' A1-like' state and a pro-regenerative ' A2-like' reactive state of astrocytes 207 is likely to be just the tip of the iceberg. In analogy to the macrophage field, which began with a binary 'M1' and 'M2' classification and eventually evolved to include a broad spectrum of cellular phenotypes 208 , omics-based approaches aimed at understanding the diverse phenotypic complexity of astrocytes will greatly enhance our knowledge and, in doing so, perhaps unveil new therapeutic targets. Given the persistent activation of astrocytes in many neuropathic pain conditions, these studies may identify distinct pro-inflammatory and anti-inflammatory, as well as pro-resolving, astrocyte phenotypes that contribute to the maintenance and resolution of pain, as has been the case in microglia 81 (Box 2).
Although astrocyte-mediated synaptogenesis during development is well-studied, little is known about the contribution of astroglia-secreted molecules to chronic pain-associated synaptogenesis in spinal and brain circuits. Given that chronic pain is chiefly driven by central sensitization via synaptic plasticity, understanding how synaptogenic mediators are utilized in the context of persistent pain thus represents a critical area of future study. Interestingly, single-cell sequencing has identified a gene expression module in astrocytes for synthesizing axonal and presynaptic components 205 .
Human astrocytes are larger than rodent astrocytes and have several distinct properties 13, 14 . Investigating changes in human astroglia in chronic pain conditions through postmortem examination and real-time imaging of astroglial activation in disease will be an area of great importance in future research.
Last, but not least, we believe that the connection between astrogliopathy and chronic pain comorbidities, such as depression, anxiety, sleep deprivation and cognitive deficits (all known to involve neuroinflammation 24 ), is an important area for future studies. Most patients with chronic pain have sleep disturbance and chronic fatigue 209 . The physiological relevance of sleep has been associated with the glymphatic system 210 , the recently identified brain-wide fluid transport system that clears proteinaceous waste and neurotoxins 40, 210 through the perivascular space formed by the vascular endfeet of astrocytes. Multiple lines of experimental work have demonstrated the existence of the glymphatic system in experimental animals (reviewed in reFS 211, 212 ) and in the human brain 213, 214 , and it has been proposed that disruption of this system could exacerbate the intracerebral accumulation of neurotoxic protein metabolites and inflammatory mediators in the CSF (Fig. 4 ), which could contribute to chronic pain development and maintenance 211 . It is currently unknown whether glymphatic function modulates acute and chronic pain, but some correlative observations exist. For example, exercise and sleep are each independently associated with improved glymphatic circulation 210, 215 and with attenuated measures of chronic pain. Likewise, the converse effect of pain on glymphatic function has yet to be determined. However, we predict that pain, especially chronic pain, could suppress glymphatic circulation through the release of noradrenaline 216 , as adrenergic activation is known to block glymphatic function 210 . Pain-associated astrogliosis could also induce a loss of perivascular AQP4 localization in order to suppress glymphatic circulation 210 .
Taken together, the evidence reviewed in this article suggests that targeting astrogliopathy, restoring the normal functions of astrocytes and/or stimulating the regenerative and pro-resolving phenotype of astrocytes will help alleviate chronic pain and its associated comorbidities.
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Nervous system injury and painful insults Nervous system injuries (such as nerve injury , spinal cord injury or stroke) and painful insults (including arthritis or tumours) result in astrogliopathy , neuroinflammation and chronic pain. To fully understand the contribution of astrocytes to chronic pain, we suggest several directions for future studies. The figure shows a schematic of the key mechanisms through which astrocytes have been proposed to influence chronic pain, each of which is a target for future investigation. Dashed arrows indicate hypotheses that remain to be tested. Research utilizing proteomics and lipidomics approaches is needed to identify the astroglial mediators produced in chronic pain conditions, as well as in physiological states. Chronic pain is chiefly an expression of maladaptive synaptic plasticity , which produces peripheral and central sensitization and thereby drives chronic pain 23 . During homeostasis, ongoing synaptic plasticity mediates the formation and breakdown of both excitatory and inhibitory synapses 16 ; however, during chronic pain conditions, this balance is perturbed, leading to increased excitatory input and reduced inhibitory input. The synaptic mechanisms responsible for this phenomenon, as well as identification of the precise astroglial synaptogenic factors that govern synapse assembly and pruning, require further investigation. It will also be of great interest to understand the connection between astrogliopathy and chronic pain comorbidities, such as depression, anxiety , cognitive deficits and sleep deprivation, as all these disorders involve neuroinflammation 24 . Sleep deprivation not only is a risk factor for clinical pain but also is associated with increased pain sensitivity in mice 236 . Importantly , sleep regulates the glymphatic system 210 , a brain-wide fluid transport system that clears proteinaceous waste 40 . It is possible that glymphatic dysfunction caused by astrogliopathy would lead to a failure to clear these waste products and an accumulation of neuroinflammatory mediators, thereby driving chronic pain. Thus, studies aimed at addressing the role of glymphatic function (and dysfunction) in acute and chronic pain conditions remain an important future direction.
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